Catalog Products » SARS-CoV-2 Spike protein (RBD, N501Y, Avi & His Tag)-HRP

SARS-CoV-2 Spike protein (RBD, N501Y, Avi & His Tag)-HRP

*This product has been discontinued!*
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. The spike protein mutation N501Y (UK variant, B.1.1.7) is one of six key contact residues within the receptor-binding domain (RBD) and has been identified as increasing binding affinity to human and murine ACE. Lineage B.1.1.7 is believed to have emerged in the United Kingdom in September 2020. Epidemiological markers suggest that the variant is more transmissible and lethal. Among the variant's several mutations is one in the receptor-binding domain of the spike protein that changes the asparagine at position 501 to tyrosine (N501Y). This mutation may cause the virus to bind more tightly to the ACE2 receptor. It is currently spread globally.
Z03595
Ask us a question
Product Introduction
Species SARS-CoV-2
Protein Construction
Spike RBD [Arg319-Ser591 (N501Y)]
Accession # P0DTC2
Avi Poly-His
N-term C-term
Conjugate HRP
Biological Activity This protein is validated to bind with human ACE2 (Cat. No. Z03516) in functional ELISA assay.
Expression System Human Cells
Application The optimal dilution ratio should be determined by the end user for specific applications.
ELISA 1:1000
Formulation Supplied as a solution in PBS, pH 7.4, 0.1% ProClin 300.
Storage & Stability Upon receiving, this product remains stable for up to 3 months at 2-8°C. Protect from light.

Background
Target Background SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. The spike protein mutation N501Y (UK variant, B.1.1.7) is one of six key contact residues within the receptor-binding domain (RBD) and has been identified as increasing binding affinity to human and murine ACE. Lineage B.1.1.7 is believed to have emerged in the United Kingdom in September 2020. Epidemiological markers suggest that the variant is more transmissible and lethal. Among the variant's several mutations is one in the receptor-binding domain of the spike protein that changes the asparagine at position 501 to tyrosine (N501Y). This mutation may cause the virus to bind more tightly to the ACE2 receptor. It is currently spread globally.
Synonyms SARS-CoV-2 SP RBD, N501Y; RBD N501Y; U.K. variant; B.1.1.7; VOC 202012/01; Alpha variant
References 1. Covid-19: New UK variant may be linked to increased death rate, early data indicate. 
2. Emergence of a new SARS-CoV-2 variant in the UK. 
3. COG-UK update on SARS-CoV-2 Spike mutations of special interest. Report 1. 19 December 2020.
 

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


feedback

Do you like the current new website?

Hate

Dislike

Neutral

Like

Love

*